SEARCH:   Advanced

Blood, 1 October 2006, Vol. 108, No. 7, pp. 2339-2348. Prepublished online as a Blood First Edition Paper on June 22, 2006; DOI 10.1182/blood-2006-02-004291. This Article Full Text (PDF) Supplemental Methods and Figure All Versions of this Article: blood-2006-02-004291v1 108/7/2339    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by van Beijnum, J. Articles by Griffioen, A. W Search for Related Content PubMed PubMed Citation Articles by van Beijnum, J. Articles by Griffioen, A. W Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 16, 2006 Accepted May 16, 2006 Gene expression of tumor angiogenesis dissected; specific targeting of colon cancer angiogenic vasculature Judy van Beijnum, Ruud P Dings, Edith van der Linden, Bernadette M Zwaans, Frans C Ramaekers, Kevin H Mayo, and Arjan W Griffioen* Angiogenesis Laboratory, Department of Pathology, Maastricht University, Maastricht, The Netherlands Department of Molecular Cell Biology, GROW, Maastricht University, The Netherlands Department of Biochemistry, Molecular Biology & Biophysics,University of Minnesota, USA * Corresponding author; email: aw.griffioen{at}path.unimaas.nl. Crucial to designing angiostatic and vascular targeting agents is the identification of target molecules. Since angiogenesis is not limited to pathologies, careful evaluation of putative therapeutic targets is warranted to prevent side effects associated with impaired physiological angiogenesis. To identify tumor-specific angiogenesis markers, we compared transcriptional profiles of angiogenic endothelial cells isolated from both malignant and non-malignant tissues with that of resting endothelial cells. We identified 17 genes that show specific overexpression in tumor endothelium but not in angiogenic endothelium of normal tissues, creating a therapeutic window for tumor vasculature specific targeting. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. Our results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Ria, K. Todoerti, S. Berardi, A. M. L. Coluccia, A. De Luisi, M. Mattioli, D. Ronchetti, F. Morabito, A. Guarini, M. T. Petrucci, et al. Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma Clin. Cancer Res., September 1, 2009; 15(17): 5369 - 5378. [Abstract] [Full Text] [PDF] T. Hosaka, H. Kimura, T. Heishi, Y. Suzuki, H. Miyashita, H. Ohta, H. Sonoda, T. Moriya, S. Suzuki, T. Kondo, et al. Vasohibin-1 Expression in Endothelium of Tumor Blood Vessels Regulates Angiogenesis Am. J. Pathol., July 1, 2009; 175(1): 430 - 439. [Abstract] [Full Text] [PDF] S. Fernando and B. S. Fletcher Targeting Tumor Endothelial Marker 8 in the Tumor Vasculature of Colorectal Carcinomas in Mice Cancer Res., June 15, 2009; 69(12): 5126 - 5132. [Abstract] [Full Text] [PDF] K. Castermans, S. P. Tabruyn, R. Zeng, J. R. van Beijnum, C. Eppolito, W. J. Leonard, P. A. Shrikant, and A. W. Griffioen Angiostatic activity of the antitumor cytokine interleukin-21 Blood, December 15, 2008; 112(13): 4940 - 4947. [Abstract] [Full Text] [PDF] W. M. Gommans, N. E. Tatalias, C. P. Sie, D. Dupuis, N. Vendetti, L. Smith, R. Kaushal, and S. Maas Screening of human SNP database identifies recoding sites of A-to-I RNA editing RNA, October 1, 2008; 14(10): 2074 - 2085. [Abstract] [Full Text] [PDF] S. B. Coffelt and A. B. Scandurro Tumors Sound the Alarmin(s) Cancer Res., August 15, 2008; 68(16): 6482 - 6485. [Abstract] [Full Text] [PDF] G. S. Butler, R. A. Dean, E. M. Tam, and C. M. Overall Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding Mol. Cell. Biol., August 1, 2008; 28(15): 4896 - 4914. [Abstract] [Full Text] [PDF] A. W. Griffioen New entry for angiostatic cancer treatment Blood, February 15, 2008; 111(4): 1755 - 1756. [Full Text] [PDF] V. L. Thijssen, S. Hulsmans, and A. W. Griffioen The Galectin Profile of the Endothelium: Altered Expression and Localization in Activated and Tumor Endothelial Cells Am. J. Pathol., February 1, 2008; 172(2): 545 - 553. [Abstract] [Full Text] [PDF] M. Mimeault and S. K. Batra Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies Ann. Onc., October 1, 2007; 18(10): 1605 - 1619. [Abstract] [Full Text] [PDF] D. M.E.I. Hellebrekers, V. Melotte, E. Vire, E. Langenkamp, G. Molema, F. Fuks, J. G. Herman, W. Van Criekinge, A. W. Griffioen, and M. van Engeland Identification of Epigenetically Silenced Genes in Tumor Endothelial Cells Cancer Res., May 1, 2007; 67(9): 4138 - 4148. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020